Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.388
R. Tamayo Bermejo, JC del Río Valencia, C. Ortega de la Cruz, I. Muñoz Castillo
{"title":"4CPS-070 Study of cardiovascular toxicity associated with ibrutinib treatment","authors":"R. Tamayo Bermejo, JC del Río Valencia, C. Ortega de la Cruz, I. Muñoz Castillo","doi":"10.1136/ejhpharm-2022-eahp.388","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.388","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126114752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.386
A. Revuelta Amallo, C. Vila Gallego, M. Vara Urruchua, M. Inclan Conde, B. Belio Aguera, M. Alvarez Lavin, M. Alonso Díez, A. Aguirrezábal Arredondo
drugs, presence of analgesia abuse, dosage, of start and end of treatment, reason for end of treatment, number of of monthly migraine headache days (MHD) prior to treatment, and number of MHD after 3 months. All the was obtained the record.
{"title":"4CPS-050 Use of galcanezumab in patients with migraine in a tertiary hospital: health results","authors":"A. Revuelta Amallo, C. Vila Gallego, M. Vara Urruchua, M. Inclan Conde, B. Belio Aguera, M. Alvarez Lavin, M. Alonso Díez, A. Aguirrezábal Arredondo","doi":"10.1136/ejhpharm-2022-eahp.386","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.386","url":null,"abstract":"drugs, presence of analgesia abuse, dosage, of start and end of treatment, reason for end of treatment, number of of monthly migraine headache days (MHD) prior to treatment, and number of MHD after 3 months. All the was obtained the record.","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"73 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126261926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.432
A. Martín López, P. Joy Carmona, CL Díaz Díaz, MÁ Ocaña Gómez, M. Ríos De Paz, M. D. De Dios García, J. Esquivel Negrín, I. González García
{"title":"6ER-015 Mutations in the factor VIII gene in our haemophilia A population","authors":"A. Martín López, P. Joy Carmona, CL Díaz Díaz, MÁ Ocaña Gómez, M. Ríos De Paz, M. D. De Dios García, J. Esquivel Negrín, I. González García","doi":"10.1136/ejhpharm-2022-eahp.432","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.432","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"09 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127395411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.396
R. Rodríguez Mauriz, L. Borràs Trias, N. García Farre, N. Almendros-Abad, N. Rudi Sola
{"title":"4CPS-130 Analysis of the different cardioversion strategies in the emergency department in a secondary hospital","authors":"R. Rodríguez Mauriz, L. Borràs Trias, N. García Farre, N. Almendros-Abad, N. Rudi Sola","doi":"10.1136/ejhpharm-2022-eahp.396","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.396","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"65 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124438008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.421
A. Gracia Moya, C. Varon Galcera, I. Cardona Pascual, E. Florensa Royo, J. Vidal Otero, G. Vancells Lujan, M. G. Gorgas Torner
{"title":"5PSQ-071 Real-world results of effectiveness and security of erenumab and galcanezumab in migraine patients","authors":"A. Gracia Moya, C. Varon Galcera, I. Cardona Pascual, E. Florensa Royo, J. Vidal Otero, G. Vancells Lujan, M. G. Gorgas Torner","doi":"10.1136/ejhpharm-2022-eahp.421","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.421","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"18 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116395223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.380
Y. Dhif, P. Bonnabry, A. Diana
Background and importanceVaccine hesitancy is one of the top 10 threats to global health according to the World Health Organization.1 A part of the Swiss population is hesitant to vaccinate against COVID-19.2Aim and objectivesThe aim of this study was to conduct a public health action with hesitant to vaccination and measure its impact on vaccine hesitancy and on vaccination rate.Material and methodsVaccine hesitancy and barriers to vaccination were measured and identified using a pre-test questionnaire. Only non-vaccinated volunteer participants were included, and they were invited to a 1-hour online session using motivational interviewing techniques, animated by a physician and a pharmacist. Two weeks after the session, they were asked to fill a post-test and 2 months later, their vaccine status was requested. Data collection was conducted from April to August 2021.Results31 adults participated for a total of 11 online sessions (2.8 participants/session). Majority were women (68%, n=21) and aged between 35 and 60 years (71%). 10 (32.3%) were public health professionals and 21 (67.7%) were not. Prior to the study, 54.9% did not consider vaccines safe (19.4% post-study), 87.1% were concerned about vaccine side effects (64.5% post-study) and 51.6% considered vaccines to be effective (83.9% post-study). Before the study, participants were classified as certainly willing to vaccinate (3.2%), probably (9.7%), probably not (35.5%), certainly not (12.9%), do not know/other (38.8%) and the degree of confidence in vaccination was 4.5 ± 2.2 (scale 1–10). After the study, the confidence increased to 6.3 ± 2.4 (+29%). Following the study, 52% (n=14) were effectively vaccinated. Among reasons that motivated to vaccinate: vaccination will help with containing the pandemic (5/14) and benefit-risk ratio is positive for the vaccine (5/14). 48% (n=13) were not vaccinated mainly for the following reasons: doubt about the effectiveness (2/13) and fear of side effects (2/13). Opinion on vaccines was moved mainly by having personal questions answered and feeling not judged for having a different opinion on vaccination.Conclusion and relevanceIn this study we could reduce vaccine hesitancy by increasing the degree of confidence in the vaccine and our action effectively convinced half the participants to get vaccinated.References and/or acknowledgements1. https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-20192. https://sotomo.ch/site/wp-content/uploads/2021/02/6.-SRG-Corona-Monitor.pdfConflict of interestNo conflict of interest
{"title":"4CPS-022 To vaccinate or not to vaccinate: impact of a public health action on vaccine hesitancy","authors":"Y. Dhif, P. Bonnabry, A. Diana","doi":"10.1136/ejhpharm-2022-eahp.380","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.380","url":null,"abstract":"Background and importanceVaccine hesitancy is one of the top 10 threats to global health according to the World Health Organization.1 A part of the Swiss population is hesitant to vaccinate against COVID-19.2Aim and objectivesThe aim of this study was to conduct a public health action with hesitant to vaccination and measure its impact on vaccine hesitancy and on vaccination rate.Material and methodsVaccine hesitancy and barriers to vaccination were measured and identified using a pre-test questionnaire. Only non-vaccinated volunteer participants were included, and they were invited to a 1-hour online session using motivational interviewing techniques, animated by a physician and a pharmacist. Two weeks after the session, they were asked to fill a post-test and 2 months later, their vaccine status was requested. Data collection was conducted from April to August 2021.Results31 adults participated for a total of 11 online sessions (2.8 participants/session). Majority were women (68%, n=21) and aged between 35 and 60 years (71%). 10 (32.3%) were public health professionals and 21 (67.7%) were not. Prior to the study, 54.9% did not consider vaccines safe (19.4% post-study), 87.1% were concerned about vaccine side effects (64.5% post-study) and 51.6% considered vaccines to be effective (83.9% post-study). Before the study, participants were classified as certainly willing to vaccinate (3.2%), probably (9.7%), probably not (35.5%), certainly not (12.9%), do not know/other (38.8%) and the degree of confidence in vaccination was 4.5 ± 2.2 (scale 1–10). After the study, the confidence increased to 6.3 ± 2.4 (+29%). Following the study, 52% (n=14) were effectively vaccinated. Among reasons that motivated to vaccinate: vaccination will help with containing the pandemic (5/14) and benefit-risk ratio is positive for the vaccine (5/14). 48% (n=13) were not vaccinated mainly for the following reasons: doubt about the effectiveness (2/13) and fear of side effects (2/13). Opinion on vaccines was moved mainly by having personal questions answered and feeling not judged for having a different opinion on vaccination.Conclusion and relevanceIn this study we could reduce vaccine hesitancy by increasing the degree of confidence in the vaccine and our action effectively convinced half the participants to get vaccinated.References and/or acknowledgements1. https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-20192. https://sotomo.ch/site/wp-content/uploads/2021/02/6.-SRG-Corona-Monitor.pdfConflict of interestNo conflict of interest","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130986035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.384
S. Coenradie, C. Batenburg, M. De Graaf-Van Der Kort, P. Langendijk
Background and importance Serious medication errors can be made during unexpected hospital admittance through the emergency ward. In particular, anticoagulants portray a great risk for patients when proper medication reconciliation is absent.We started using pharmacy practitioners (PPs) to improve this process on the emergency ward. We report here the results of two case series with respect to accuracy in the medication reconciliation on the emergency room (ER) ward. Aim and objectives To investigate if appropriate embedding of PPs in the process of medication reconciliation during unexpected admittance to the hospital could lead to fewer medication errors downstream in other hospital wards. Material and methods A PP was embedded in the ER ward team during office hours (08:00 to 17:00) to perform the medication reconciliation of unexpectedly admitted patients instead of ER physicians. The two case series of admitted patients were chosen in a post-propter design. As a zero measurement, a case series of patients (ZMCS) in a pilot phase was used (October-December 2019). This pilot phase was done to collect data on hospital administration in order to show that PPs could be embedded to do this task. This retrospective dataset consisted of 40 patients, unexpectedly admitted on the ER ward and for whom the ER physicians performed the medication reconciliation. A prospective case series of patients was then performed during the period October-December 2020 under the same conditions and used as the experimental case series (EXCS) to compare with the ZMCS. The number of medication errors in the EXCS divided by the number of medication errors during the ZMCS was our main outcome parameter expressed as a percentage. After ER admittance patients were transmitted to several other specialist wards. Results Our results showed a 40% reduction in medication errors downstream in the specialist wards when the PPs were involved in the medication reconciliation process in the EXCS compared to the medication reconciliation done by ER physicians in the ZMCS. Conclusion and relevance We conclude that PPs can make a valuable contribution to reduce the number of medication errors downstream in the hospital when embedded in the ER ward team.
{"title":"4CPS-032 How to improve the appropriate prescription of anticoagulants during unexpected emergency room admittance to the hospital? A case series report using pharmacy practitioners","authors":"S. Coenradie, C. Batenburg, M. De Graaf-Van Der Kort, P. Langendijk","doi":"10.1136/ejhpharm-2022-eahp.384","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.384","url":null,"abstract":"Background and importance Serious medication errors can be made during unexpected hospital admittance through the emergency ward. In particular, anticoagulants portray a great risk for patients when proper medication reconciliation is absent.We started using pharmacy practitioners (PPs) to improve this process on the emergency ward. We report here the results of two case series with respect to accuracy in the medication reconciliation on the emergency room (ER) ward. Aim and objectives To investigate if appropriate embedding of PPs in the process of medication reconciliation during unexpected admittance to the hospital could lead to fewer medication errors downstream in other hospital wards. Material and methods A PP was embedded in the ER ward team during office hours (08:00 to 17:00) to perform the medication reconciliation of unexpectedly admitted patients instead of ER physicians. The two case series of admitted patients were chosen in a post-propter design. As a zero measurement, a case series of patients (ZMCS) in a pilot phase was used (October-December 2019). This pilot phase was done to collect data on hospital administration in order to show that PPs could be embedded to do this task. This retrospective dataset consisted of 40 patients, unexpectedly admitted on the ER ward and for whom the ER physicians performed the medication reconciliation. A prospective case series of patients was then performed during the period October-December 2020 under the same conditions and used as the experimental case series (EXCS) to compare with the ZMCS. The number of medication errors in the EXCS divided by the number of medication errors during the ZMCS was our main outcome parameter expressed as a percentage. After ER admittance patients were transmitted to several other specialist wards. Results Our results showed a 40% reduction in medication errors downstream in the specialist wards when the PPs were involved in the medication reconciliation process in the EXCS compared to the medication reconciliation done by ER physicians in the ZMCS. Conclusion and relevance We conclude that PPs can make a valuable contribution to reduce the number of medication errors downstream in the hospital when embedded in the ER ward team.","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"9 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131564704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.381
I. Patier, N. Herranz-Muñoz, F. Fernandez Fraga, J. Sánchez-Rubio Ferrández, I. García-Bermejo, M. Moreno-García, T. Molina-García
{"title":"4CPS-025 Adequacy of hepatitis B reactivation prophylaxis in patients treated with rituximab","authors":"I. Patier, N. Herranz-Muñoz, F. Fernandez Fraga, J. Sánchez-Rubio Ferrández, I. García-Bermejo, M. Moreno-García, T. Molina-García","doi":"10.1136/ejhpharm-2022-eahp.381","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.381","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"123 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114191624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.394
N. Herranz-Muñoz, J. Sánchez-Rubio Ferrández, L. Martín-Zaragoza, M. Gómez-Bermejo, S. Solís-Cuñado, T. Molina-García
{"title":"4CPS-126 Real-world persistence with fampridine among multiple sclerosis patients","authors":"N. Herranz-Muñoz, J. Sánchez-Rubio Ferrández, L. Martín-Zaragoza, M. Gómez-Bermejo, S. Solís-Cuñado, T. Molina-García","doi":"10.1136/ejhpharm-2022-eahp.394","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.394","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114823976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.405
C. Martinez-Molina, N. Pages, P. Riera, A. Riera, H. Codes, C. Díaz-Torné, H. Corominas, J. Ruiz-Ramos, M. Masip
{"title":"4CPS-215 Persistence and therapeutic adherence to first-generation Janus kinase inhibitors in rheumatoid arthritis patients","authors":"C. Martinez-Molina, N. Pages, P. Riera, A. Riera, H. Codes, C. Díaz-Torné, H. Corominas, J. Ruiz-Ramos, M. Masip","doi":"10.1136/ejhpharm-2022-eahp.405","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.405","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130084291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：